Otsuka Holdings Co.,Ltd. FY2026 Q2 Earnings Report

Quick View

Executive Summary

Driven by its core Pharmaceuticals Business, the company posted higher revenue and earnings, with an improvement in its operating margin. Revenue was ¥13,323.9B (+12.8% YoY), while Operating Income was ¥2,785.4B (+15.0% YoY), securing an earnings growth rate that exceeded the revenue growth rate. Profit Before Tax was ¥2,854.2B (+26.1% YoY), and Net Income attributable to owners of the parent was ¥2,156.1B (+24.3% YoY), supported by an improvement in net financial income and contributions from equity-method income. The operating margin improved from the previous year to 20.9%, while progress against the full-year plan was 48.9% for Revenue, compared with 59.4% for Operating Income and 60.7% for Net Income, indicating that earnings progress is leading revenue progress.

Factors Affecting Performance

【Revenue】All segments posted revenue growth. The core Pharmaceuticals segment, which accounts for 71.4% of the revenue mix, led company-wide growth with revenue of ¥9,516.1B (+14.1% YoY). Nutraceuticals recorded ¥3,001.3B (+8.7% YoY), Other Businesses ¥632.1B (+14.7% YoY), and Consumer Products ¥174.4B (+10.1% YoY), with all segments securing revenue growth.

【Profit and Loss】Operating Income was ¥2,785.4B (+15.0% YoY). With the gross margin maintained at a high level of 72.5%, the SG&A expense ratio was controlled at 40.1%, broadly in line with the previous year, resulting in an operating margin of 20.9%. Financial income of ¥116.3B exceeded financial expenses of ¥47.6B and contributed to earnings growth on a net basis. In addition, equity-method income of ¥202.1B contributed to Profit Before Tax of ¥2,854.2B (+26.1% YoY), which exceeded the growth rate of Operating Income. Net Income attributable to owners of the parent was ¥2,156.1B (+24.3% YoY), with the effective tax rate remaining broadly at the previous year’s level. The company achieved both revenue and earnings growth, and the fact that earnings growth (+15.0%〜+24.3%) exceeded revenue growth (+12.8%) indicates contributions from both operating leverage and non-operating factors.

Segment Analysis

Pharmaceuticals generated revenue of ¥9,516.1B (71.4% mix, YoY+14.1%), Operating Income of ¥2,504.1B (YoY+16.3%), and a margin of 26.3%. As the core business generating the majority of company-wide earnings, it secured an earnings growth rate exceeding its revenue growth rate. Nutraceuticals recorded revenue of ¥3,001.3B (YoY+8.7%), while Operating Income was limited to ¥368.5B (YoY+0.5%). Its margin was 12.3%, broadly flat from the previous year, and earnings growth commensurate with revenue growth was not achieved. Other Businesses (including OperatingSegmentsNotIncludedInReportableSegments, etc.) recorded revenue of ¥632.1B (YoY+14.7%), Operating Income of ¥61.6B (YoY+23.0%), and a margin of 9.8%, with earnings growth exceeding revenue growth. Consumer Products posted revenue of ¥174.4B (YoY+10.1%), Operating Income of ¥138.1B (YoY+7.4%), and an exceptionally high margin of 79.2%, although its earnings growth rate was slightly below its revenue growth rate. There are substantial differences in margins among segments, and company-wide margin fluctuations are highly sensitive to the performance of Pharmaceuticals.

Key Financial Indicators

【Profitability】The operating margin improved from the previous year to 20.9%, while the gross margin remained at the high level of 72.5%. The SG&A expense ratio was broadly unchanged from the previous year at 40.1%. 【Cash Flow Quality】Operating Cash Flow (OCF) was ¥2,171.1B (+2.1% YoY), representing approximately 1.01x Net Income attributable to owners of the parent of ¥2,156.1B, indicating strong cash backing for earnings. 【Investment Efficiency】ROE was 6.6% (improved from the previous year), while R&D expenses were ¥1,721.7B (12.9% of Revenue), maintaining an investment level commensurate with revenue growth. 【Financial Soundness】The Equity Ratio was 73.7% (improved from 72.3% in the previous year). Total bonds and borrowings, including current and non-current liabilities, amounted to only ¥946.6B, substantially below cash on hand of ¥4,695.5B, indicating an extremely sound financial position.

Cash Flow Analysis

Operating Cash Flow was ¥2,171.1B (+2.1% YoY). Against the subtotal before changes in working capital of ¥2,586.6B, increases in inventories (-¥349.2B) and income taxes paid (-¥483.7B) were factors weighing on cash flow. Investing Cash Flow was -¥1,730.1B. In addition to capital expenditures (-¥449.4B), the acquisition of intangible assets represented a substantial cash requirement, indicating that funds were allocated to growth investments. Free Cash Flow (Operating Cash Flow + Investing Cash Flow) was ¥441.0B, somewhat insufficient to cover the principal components of Financing Cash Flow (-¥1,143.2B), namely dividend payments (-¥388.5B) and share repurchases (-¥299.3B). However, given cash on hand of ¥4,695.5B, there has been no liquidity issue. Cash and cash equivalents declined from ¥4,695.5B in the previous year, indicating that the combination of shareholder returns and growth investments resulted in cash outflows.

Quality of Earnings

The operating margin of 20.9%, which represents the earning power of the core business, formed the core of profits. Outside the operating business, financial income of ¥116.3B exceeded financial expenses of ¥47.6B and contributed to earnings growth on a net basis. Equity-method income of ¥202.1B accounted for approximately 7% of Profit Before Tax of ¥2,854.2B and functioned as a diversification benefit of the business portfolio. The net difference between Other Income of ¥72.1B and Other Expenses of ¥52.0B was a modest +¥20.2B, indicating that the impact of temporary factors was limited. Operating Cash Flow (¥2,171.1B) exceeded Net Income attributable to owners of the parent (¥2,156.1B), with a ratio of approximately 1.01x, indicating strong cash backing for earnings. However, the increase in inventories (-¥349.2B) should be noted as a factor that somewhat reduces earnings quality from an accrual perspective.

Earnings Forecast and Guidance

The full-year plan calls for Revenue of ¥27,250.0B, Operating Income of ¥4,690.0B (-2.2% YoY), and Net Income of ¥3,600.0B (-2.2% YoY), implying earnings declines. Progress in the first half was 48.9% for Revenue (13,323.9/27,250.0), 59.4% for Operating Income (2,785.4/4,690.0), and 60.7% for Net Income (2,156.1/3,550.0, attributable to owners of the parent), with earnings progress exceeding revenue progress in all cases. In contrast to the substantial earnings growth in the first half, the full-year plan assumes earnings declines. The plan appears to incorporate the possibility of a slowdown in earnings growth in the second half due to increases in R&D expenses and SG&A expenses, as well as the reversal of the earnings-boosting effect of financial income seen in the first half. During the current quarter, both the earnings forecast and the dividend forecast were revised.

Shareholder Returns

The interim dividend was ¥100 per share, an increase of +¥30 (+42.9%) from ¥70 in the same period of the previous year. The full-year dividend forecast is ¥200 per share. Total interim dividend payments, based on the number of shares issued after excluding treasury shares, were approximately ¥525.4B, resulting in a Payout Ratio of approximately 24.4% against first-half Net Income attributable to owners of the parent of ¥2,156.1B. Share repurchases of ¥299.3B were conducted. The Total Return Ratio, combining dividends (¥388.5B on a cash flow payment basis) and share repurchases, was approximately 31.9% (¥687.8B/¥2,156.1B). Given the Equity Ratio of 73.7% and ample cash on hand, the current level of shareholder returns is balanced with the company’s financial position.

Risk Factors

1. Increase in inventories: Inventories were ¥4,139.1B, up +10.6% from ¥3,743.2B in the previous year. While this appears to reflect inventory accumulation to secure supply and accommodate new products, inventory stagnation could lead to delays in cash conversion and the risk of valuation losses.

2. Business concentration risk: Pharmaceuticals accounts for 71.4% of the revenue mix and the majority of Operating Income, resulting in a structure in which company-wide performance is highly dependent on the performance of this business.

3. Increase in intangible assets and goodwill: Intangible fixed assets increased to ¥6,910.5B (+20.4% from ¥5,741.3B in the previous year), while goodwill increased to ¥5,262.9B (+3.2% YoY). Combined, they account for 27.7% of total assets. The potential impact of impairment losses in the future should be closely monitored.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

The company’s operating margin of 20.9% reflects the high profitability characteristic of the pharmaceutical industry.

Growth and Capital Efficiency

The double-digit revenue growth rate indicates a high level of growth even within the industry.

※Source: Compiled by the Company

Key Takeaways from the Earnings Results

1. Operating Income and Net Income growth (+15.0%〜+24.3%) exceeded revenue growth (+12.8%), confirming growth accompanied by earnings quality as a result of the continued high gross margin of 72.5%, control of the SG&A expense ratio, and an improvement in net financial income.

2. First-half progress against the full-year plan was higher on the earnings side (59.4% for Operating Income and 60.7% for Net Income) than on the revenue side (48.9%). A key characteristic is that the full-year plan itself is conservatively set to assume earnings declines from the previous year.

3. The interim dividend was increased from ¥70 in the previous year to ¥100, while share repurchases continued. At the same time, increases in inventories, intangible assets, and goodwill were observed as changes on the balance sheet.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly disclosed data using a residual income model (Ohlson-type model with an explicit five-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥6,596〜¥6,993 at Cost of Equity ±1%; ¥6,775〜¥6,814 at ω±0.1.

Notes:

• As progress of Net Income against the full-year forecast (61%) exceeds the standard level (50%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies with progress ahead of plan tend to exceed forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Net assets as of the quarter-end are used (there is a timing difference relative to the full-year forecast).

(Calculation model: Residual Income Model / Interest Rate Reference Month: 2026-06 / This figure does not forecast or guarantee future share prices)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with a professional as necessary.

---End of Report---